drugset / Trial / NCT01010100

Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care

NCT01010100

Phase 3 Completed 204 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine if the administration of small doses of Acarbose can prevent or delay the appearance of Type 2 Diabetes Mellitus in a population of subjects with prediabetes.

Timeline

Start
2000-08
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 50 mg

Indications